王萍;尹晓岚;张北华;唐旭东;

• 1:中国中医科学院西苑医院
• 2:中国中医科学院

摘要(Abstract)：

慢性萎缩性胃炎(CAG)及胃癌前病变(GPL)诊治在胃癌防治中占有重要地位。近40年来CAG及GPL的中医药研究在疾病诊断、风险监测、临床治疗、基础研究等方面取得了一定成果,但仍在目标定位、诊断规范性、研究科学性、疗效评价指标认可度等方面存在问题,严重影响研究的质量,制约中医药疗效和优势的体现。通过对上述问题的系统梳理,提出应以大数据为依托,制定病证结合的风险预测模型,从而制定适合我国国情的有效风险评估工具;建议统一CAG及GPL的诊断标准、细化病变分级分型标准,并及早采用中药进行有效干预。

关键词(KeyWords)： 慢性萎缩性胃炎;胃癌前病变;中医药研究

Abstract:

Keywords:

基金项目(Foundation): 国家重点研发计划项目(2017YFC1700601);; 国家中医药管理局国家中医临床研究基地业务建设科研专项(JDZX2015265)

作者(Author): 王萍;尹晓岚;张北华;唐旭东;

Email:

DOI: 10.13288/j.11-2166/r.2020.22.006

参考文献(References)：

• [1]NAGAYO T.Histological diagnosis of biopsied gastric mucosa with special reference to that of borderline lesions[J].Gann Monogr,1971,11:245-256.
• [2]CHIU PWY,UEDO N,SINGH R,et al.An Asian consensus on standards of diagnostic upper endoscopy for neoplasia [J].Gut,2019,68(2):186-197.
• [3]杜奕奇,蔡全才,廖专,等.中国早期胃癌筛查流程专家共识意见(草案)(2017年,上海)[J].胃肠病学,2018,23(2):92-97.
• [4]SUGANO K,TACK J,KUIPERS EJ,et al.Kyoto global consensus report on Helicobacter pylori gastritis[J].Gut,2015,64(9):1353-1367.
• [5]中华医学会消化病学分会.中国慢性胃炎共识意见[J].胃肠病学,2017,22(11):670-687.
• [6]KIMURA K,TAKEMOTO T.(1969)An endoscopic recognition of the atrophic border and its significance in chronic gastritis[J].Endoscopy,1969,1(3):87-97.
• [7]MASUYAMA H,YOSHITAKE N,SASAI T,et al.Relationship between the degree of endoscopic atrophy of the gastric mucosa and carcinogenic risk[J].Digestion,2015,91(1):30-36.
• [8]RUGGE M,BONI M,PENNELLI G,et al.Gastritis OLGA-staging and gastric cancer risk:a twelve-year clinico-pathological follow-up study[J].Aliment Pharmacol Ther,2010,31(10):1104-1111.
• [9]QUACH DT,LE HM,NGUYEN OT,et al.The severity of endoscopic gastric atrophy could help to predict operative link on gastritis assessment gastritis stage[J].J Gastroenterol Hepatol,2011,26(2):281-285.
• [10]YOSHIDA T,KATO J,INOUE I,et al.Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer[J].Int J Cancer,2014,134(6):1445-1457.
• [11]MIKI K.Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels:“ABC method” [J].Proc Jpn Acad,2011,87(7):405-414.
• [12]吕宾.重视胃癌的筛查和早期诊断[J].浙江医学,2018,40(14):1521-1522.
• [13]DIMIS-RIBEIRO M,AREIA M,VRIES AC,et al.Management of precancerous conditions and lesions in the stomach (MAPS) [J].Endoscopy,2012,44(1):74-94.
• [14]PIMENTEL-NUNES P,LIBANIO D,MARCOS-PINTO R,et al.Management of epithelial precancerous conditions and lesions inthe stomach (MAPS II) [J].Endoscopy,2019,51(4):365-388.
• [15]KIM SS,KOOK MC,SHIN OR,et al.Factors to improve the interobserver agreement for gastric atrophy and intestinal metaplasia :consensus of definition and criteria[J].Histopathology,2018,72(5):838-845.
• [16]SUNG JK.Diagnosis and management of gastric dysplasia[J].Korean J Intern Med,2016,31(2):201-209.
• [17]周炜洵,金栏.慢性胃炎及上皮性肿瘤胃黏膜活检病理诊断共识[J].中华病理学杂志,2017,46(5):289-293.
• [18]张声生,李乾构,唐旭东,等.慢性萎缩性胃炎中医诊疗共识意见[J].中医杂志,2010,51 (8):749-753.
• [19]中国中西医结合学会消化系统疾病专业委员会.慢性萎缩性胃炎中西医结合诊疗共识意见[J].中国中西医结合消化杂志,2018,25(2):122-131.
• [20]TANG XD,ZHOU LY,ZHANG ST,et al.A randomized double-blind clinical trial of moluodan for the treatment of chronic atrophic gastritis with dysplasia[J].Chin J Integr Med,2016,22(1):9-18.